REGN
US EQUITY
Health Care
Biotechnology
CIK: 872589
Regeneron Pharmaceuticals (REGN) Quant Factor Diagnostic & Fair Value Model
Regeneron Pharmaceuticals (Ticker: REGN) is listed in the Health Care sector (Biotechnology). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$805.02
-1.72%
Latest Close (2026-10-23)
Market Cap: $83.13B
P/E Ratio: 16.5
Momentum Strength
3M / 12M
+20.66%
1M: +1.13%
12M: +37.67%
Quality (ROE)
Point-in-Time
+16.36%
Trailing Return on Equity
Technical Trend
RSI 14
74.0
SMA50: $791.37
SMA200: $736.01
Valuation Multiplier
Trailing
16.5
Moderate Valuation Corridor (15x - 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Moderate Valuation Corridor (15x - 30x P/E)
REGN trades within a typical sector multiple band (16.5x P/E), broadly aligned with trailing earnings.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 8/9 (High Financial Strength)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 872589 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-30 | 2026-07-30 | - | $1.30B | $1.89B | $12.23 |
| 10-Q | 2026-03-31 | 2026-07-30 | - | $727.20M | $1.08B | $6.75 |
| 10-Q | 2025-12-31 | 2026-07-30 | - | - | - | - |
| 10-Q | 2025-06-30 | 2026-07-30 | - | $1.39B | $2.19B | $12.81 |
| 10-Q | 2025-03-31 | 2026-07-30 | - | $808.70M | $1.05B | $7.27 |
| 10-K | 2025-12-31 | 2026-02-04 | - | $4.50B | $4.98B | $41.48 |
| 10-K | 2024-12-31 | 2026-02-04 | - | $4.41B | $4.42B | $38.34 |
| 10-K | 2023-12-31 | 2026-02-04 | - | $3.95B | $4.59B | $34.77 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Regeneron Pharmaceuticals (REGN) valuation multiples, momentum factors, and point-in-time filing conventions.
How should REGN's current valuation multiple be interpreted? ↓
REGN trades at a trailing P/E of 16.5x within the Health Care sector (moderate valuation corridor (15x - 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are REGN's key momentum and technical factor indicators? ↓
As of the latest close, REGN shows a 1-month return of +1.13%, 3-month return of +20.66%, and 12-month return of +37.67%, with a 14-day RSI of 74.0. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for REGN? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can REGN be incorporated into systematic factor models? ↓
REGN can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.